Maxim Remains Cautious on Neuralstem, Inc. Following 4Q:14: Update
Maxim Group's healthcare analyst Jason Kolbert came out with a negative view on Neuralstem, Inc. (NYSE MKT:CUR), after the company reported its fourth-quarter results and provided updates on its pipeline.
Kolbert noted, "Neuralstem highlighted multiple programs that all sound very exciting but as we break the details down we find ourselves as non-believers: ALS (NSI-566), ischemic stroke (NSI-566), spinal cord injury (NSI-566), genetically altered neural stem cells (NSI-532), major depressive disorder (NSI-189), and schizophrenia (NSI-189)."
Furthermore, "We believe that competing cell therapy-based companies offer alternative and safer cell-based therapeutic options that are more advanced clinically for ALS. Additionally, the company's mood disorder small molecule, NSI-189, a product the company tried to sell and failed, is in very early stages and unproven."
The analyst rates the stock a Sell with a $0.25 price target, which implies a downside of 89% from current levels.
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 11.8% and a 46.2% success rate. Kolbert is ranked #260 out of 3535 analysts.